JVAQX
Price
$38.16
Change
-$1.09 (-2.78%)
Updated
Dec 18 closing price
RMFCX
Price
$54.22
Change
-$1.42 (-2.55%)
Updated
Dec 18 closing price
Ad is loading...

JVAQX vs RMFCX

Header iconJVAQX vs RMFCX Comparison
Open Charts JVAQX vs RMFCXBanner chart's image
JPMorgan Value Advantage R4
Price$38.16
Change-$1.09 (-2.78%)
VolumeN/A
CapitalizationN/A
American Funds American Mutual R3
Price$54.22
Change-$1.42 (-2.55%)
VolumeN/A
CapitalizationN/A
JVAQX vs RMFCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
JVAQX vs. RMFCX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JVAQX is a Hold and RMFCX is a Buy.

FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 98.7B vs. JVAQX (9.03B). RMFCX pays higher dividends than JVAQX: RMFCX (1.69) vs JVAQX (1.45). JVAQX was incepted earlier than RMFCX: JVAQX (8 years) vs RMFCX (23 years). RMFCX (25.00) and JVAQX (24.00) have comparable annual turnover. JVAQX has a lower initial minimum investment than RMFCX: JVAQX (0) vs RMFCX (250). RMFCX annual gain was more profitable for investors over the last year : 12.63 vs. JVAQX (10.51). RMFCX return over 5 years is better than : 40.39 vs. JVAQX (10.46).
JVAQXRMFCXJVAQX / RMFCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years23 years-
Gain YTD9.51511.42383%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets9.03B98.7B9%
Annual Yield % from dividends1.451.6986%
Returns for 1 year10.5112.6383%
Returns for 3 years2.9814.1621%
Returns for 5 years10.4640.3926%
Returns for 10 yearsN/A61.84-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REKR0.83N/A
-0.01%
Rekor Systems
CRBG29.99-0.44
-1.45%
Corebridge Financial
WHD61.48-1.46
-2.32%
Cactus
ABCL2.79-0.07
-2.45%
AbCellera Biologics
TRIB0.85-0.05
-5.67%
Trinity Biotech plc